Leerink Partnrs Has Bullish Outlook for Cencora Q4 Earnings

Cencora, Inc. (NYSE:COR - Free Report) - Equities research analysts at Leerink Partnrs upped their Q4 2025 earnings per share estimates for Cencora in a report issued on Tuesday, July 1st. Leerink Partnrs analyst M. Cherny now anticipates that the company will post earnings of $3.85 per share for the quarter, up from their prior estimate of $3.84. The consensus estimate for Cencora's current full-year earnings is $15.37 per share. Leerink Partnrs also issued estimates for Cencora's FY2026 earnings at $17.51 EPS, FY2027 earnings at $19.26 EPS and FY2028 earnings at $21.16 EPS.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, beating the consensus estimate of $4.07 by $0.35. Cencora had a net margin of 0.55% and a return on equity of 344.71%. The firm had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. During the same quarter in the prior year, the firm earned $3.80 EPS. Cencora's revenue for the quarter was up 10.3% on a year-over-year basis.

Several other brokerages also recently weighed in on COR. Wall Street Zen upgraded Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Morgan Stanley set a $288.00 price objective on shares of Cencora in a research report on Tuesday, April 15th. Robert W. Baird boosted their price objective on shares of Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Wells Fargo & Company upgraded shares of Cencora from an "equal weight" rating to an "overweight" rating and raised their target price for the stock from $274.00 to $337.00 in a research note on Tuesday, June 3rd. Finally, Jefferies Financial Group boosted their price target on shares of Cencora from $275.00 to $300.00 and gave the stock a "hold" rating in a research note on Monday. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to MarketBeat.com, Cencora presently has an average rating of "Moderate Buy" and an average target price of $306.33.

Cencora Stock Performance

COR stock traded up $5.06 during trading on Wednesday, hitting $296.23. The company had a trading volume of 614,990 shares, compared to its average volume of 1,504,083. The firm has a 50-day moving average price of $290.91 and a 200-day moving average price of $266.76. The company has a quick ratio of 0.52, a current ratio of 0.87 and a debt-to-equity ratio of 6.01. The firm has a market cap of $57.42 billion, a PE ratio of 34.37, a price-to-earnings-growth ratio of 1.44 and a beta of 0.57. Cencora has a 1-year low of $218.65 and a 1-year high of $309.35.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in COR. Oppenheimer & Co. Inc. increased its stake in shares of Cencora by 1.7% during the 4th quarter. Oppenheimer & Co. Inc. now owns 5,949 shares of the company's stock worth $1,337,000 after purchasing an additional 99 shares in the last quarter. SVB Wealth LLC acquired a new stake in Cencora during the 4th quarter valued at $431,000. Fisher Asset Management LLC increased its position in Cencora by 17.7% during the fourth quarter. Fisher Asset Management LLC now owns 1,091 shares of the company's stock worth $245,000 after buying an additional 164 shares in the last quarter. Bridges Investment Management Inc. raised its holdings in shares of Cencora by 16.4% in the fourth quarter. Bridges Investment Management Inc. now owns 1,908 shares of the company's stock worth $429,000 after acquiring an additional 269 shares during the last quarter. Finally, Smartleaf Asset Management LLC raised its holdings in shares of Cencora by 39.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,108 shares of the company's stock worth $249,000 after acquiring an additional 314 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company's stock.

Insider Activity

In related news, Chairman Steven H. Collis sold 14,579 shares of Cencora stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $292.62, for a total transaction of $4,266,106.98. Following the completion of the transaction, the chairman directly owned 311,913 shares of the company's stock, valued at approximately $91,271,982.06. The trade was a 4.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Robert P. Mauch sold 4,969 shares of the business's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $289.33, for a total value of $1,437,680.77. Following the sale, the chief executive officer owned 47,582 shares in the company, valued at approximately $13,766,900.06. The trade was a 9.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 34,127 shares of company stock worth $9,812,296 over the last 90 days. 10.80% of the stock is currently owned by company insiders.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Investors of record on Friday, May 16th were issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.74%. The ex-dividend date was Friday, May 16th. Cencora's dividend payout ratio is currently 25.52%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.